Bruce N. Jacobs, Chief Financial Officer at Kymera Therapeutics, Inc. (KYMR), sold 77,109 shares at $110.54 ($8.9M) on 2026-06-30, disclosed to the SEC on 2026-07-02.
Scheduled sale ($8.9M) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $110.54 | 1,500 | $166K | 1.9% |
| 2 | $111.57 | 1,700 | $190K | 2.1% |
| 3 | $112.79 | 1,100 | $124K | 1.4% |
| 4 | $114.19 | 4,110 | $469K | 5.3% |
| 5 | $114.77 | 51,375 | $5.9M | 66.5% |
| 6 | $115.82 | 7,971 |
| $923K |
| 10.4% |
| 7 | $116.99 | 6,153 | $720K | 8.1% |
| 8 | $117.70 | 3,200 | $377K | 4.2% |
| Total | $114.96 avg | 77,109 | $8.9M | 100% |
| Filing → |
| KYMR | SELL | 2025-03-03 | $389K | — | Filing → |
| KYMR | SELL | 2024-03-04 | $318K | — | Filing → |
| KYMR | SELL | 2023-03-03 | $42K | — | Filing → |